Clinical Trial Update: Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update evaluating a CD19-targeted CAR-T therapy for relapsed/refractory CD19-positive B cell leukemia and lymphoma (early-phase study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Leukemia B-cell
• Leukemia Lymphocytic Chronic B-cell
• Lymphoma

Drugs mentioned

• CD19-targeted CAR-T Therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN